CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Gordon James who wrote (429)	12/5/1999 11:38:00 AM
From: scaram(o)uche	Read Replies (2) of 666

Gordon: Bex responses sometimes take many months to complete I'm presuming that, as far as "tranformed cell load" is concerned, that the responses are completed early, but that it just takes time for patient appearance (node architecture, etc.) to catch up? Or is an issue of damaged cells that are not replication-competent sitting around and making it look like the patient isn't CR when they actually are? Can you find some brains to pick regarding what's happening in the interval 3-6 months followup? Apologize if I'm asking naive questions that have been addressed previously. Staying on the "naive" front.... why were 24 patients non-evaluable? I am starting to believe that we will find Bex+Flu to be superior to Rit+CHOP in term of safety profile as well That would win the day. That would win the day. That would win the day! gotta get some shuteye now! I'm adding to the chorus of "thank yous", big-time. Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next